SB
SBMJF.US Dimerix Ltd
- Market cap
- USD 210M
- P/E
- -
- P/B
- 24.04x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is SBMJF.US undervalued?
Graham numberThe Graham number of Dimerix Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Dimerix Ltd fundamental analysis
No fundamental analysis for Dimerix Ltd yet.
Dimerix Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Dimerix Ltd
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease; as well as DMX-652 for the treatment of acute kidney injury. The company is headquartered in Fitzroy, Australia.
Full company profileDimerix Ltd financial statements
Dimerix Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | - | - | - | 407K | 5.59M | 4.35M |
| Gross Profit | - | - | - | 407K | 5.59M | 4.35M |
| Operating Income | -10.9M | -17.0M | -22.8M | -25.2M | -32.0M | -37.2M |
| EBITDA | - | - | -22.8M | -25.2M | -31.9M | -37.0M |
| Net Income | -6.37M | -10.5M | -13.8M | -17.1M | -13.3M | -29.8M |
| EPS | -0.03 | -0.03 | -0.04 | -0.03 | -0.02 | -0.05 |
| Balance Sheet | ||||||
| Total Assets | 9.42M | 16.5M | 17.8M | 32.1M | 91.2M | 58.6M |
| Total Liabilities | 7.95M | 2.07M | 11.8M | 13.9M | 77.8M | 73.3M |
| Shareholders' Equity | 1.47M | 14.4M | 5.96M | 18.2M | 13.4M | -14.8M |
| Cash & Short-term Investments | 5.25M | 9.63M | 7.99M | 22.1M | 68.3M | 16.2M |
| Cash Flow | ||||||
| Capital Expenditure | 9.57K | 10.6K | 2.30K | 15.8K | 21.0K | 4.98K |
| Free Cash Flow | -6.37M | -13.4M | -12.7M | -7.02M | 39.0M | -51.8M |
| Ratios | ||||||
| ROE | -433.9% | -72.7% | -231.5% | -93.9% | -99.0% | - |
| ROA | -67.6% | -63.6% | -77.7% | -53.2% | -14.5% | -50.9% |
| Net Profit Margin | - | - | - | -4,190.6% | -237.2% | -685.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Dimerix Ltd dividends
Dimerix Ltd has not paid dividends in the last 6 fiscal years.
Last stock split: 1:20 on Oct 23, 2017.
Who owns Dimerix Ltd
- Insiders 22.23%
- Institutions 2.70%
- Public & others 75.07%
- Shares outstanding 600M
- Free float 464M
Dimerix Ltd company profile
- Company name
- Dimerix Ltd
- Ticker
- SBMJF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 15
- Fiscal year end
- June
- Address
- 425 Smith Street, Fitzroy, VIC, Australia, 3065
- Phone
- 1300 813 321
- Website
- dimerix.com
About Dimerix Ltd
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease; as well as DMX-652 for the treatment of acute kidney injury. The company is headquartered in Fitzroy, Australia.
Dimerix Ltd management
5- Dr. Nina Webster B.Sc., M.B.A., M.IP.Law, Ph.D.CEO, MD & Director
- Mr. Michael Tonroe ACA, B.Sc., Bsc(Hons), F.C.A., M.A.I.C.D.CFO & Company Secretary · born 1966
- Dr. Robert ShepherdChief Operating Officer
- Dr. David Everett Fuller BPharm, M.D., MBBSChief Medical Officer · born 1964
- Mr. Kevin Donald George Pfleger BA (Hons), MA, Ph.D.Chief Scientific Advisor